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Abstract
Plasma is the most easily accessible source for biomarker discovery in clinical proteomics. However, identifying potential
biomarkers from plasma is a challenge given the large dynamic range of proteins. The potential biomarkers in plasma are
generally present at very low abundance levels and hence identification of these low abundance proteins necessitates the
depletion of highly abundant proteins. Sample pre-fractionation using immuno-depletion of high abundance proteins using
multi-affinity removal system (MARS) has been a popular method to deplete multiple high abundance proteins. However,
depletion of these abundant proteins can result in concomitant removal of low abundant proteins. Although there are some
reports suggesting the removal of non-targeted proteins, the predominant view is that number of such proteins is small. In
this study, we identified proteins that are removed along with the targeted high abundant proteins. Three plasma samples
were depleted using each of the three MARS (Hu-6, Hu-14 and Proteoprep 20) cartridges. The affinity bound fractions were
subjected to gelC-MS using an LTQ-Orbitrap instrument. Using four database search algorithms including MassWiz
(developed in house), we selected the peptides identified at ,1% FDR. Peptides identified by at least two algorithms were
selected for protein identification. After this rigorous bioinformatics analysis, we identified 101 proteins with high
confidence. Thus, we believe that for biomarker discovery and proper quantitation of proteins, it might be better to study
both bound and depleted fractions from any MARS depleted plasma sample.
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Introduction
Proteomics is an important tool to identify relevant biomarkers
for prognosis or diagnosis of various diseases. Plasma is the most
preferred diagnostic material for disease proteomic studies due to
its non-invasive nature. It is a heterogeneous collection of proteins
secreted or leaked from all types of tissues revealing the cellular
state due to spatio-temporal differences in protein expression.
Thus, being a direct reflection of the patho-physiological condition
of a patient, it is considered to be a diagnostic goldmine for
biomarkers[1]. But, it is also one of the most difficult body fluids to
work with because of the sample complexity and wide dynamic
range of abundance spanning .12 orders of magnitude[2].
Many studies have emphasized the importance of plasma as a
treasure-trove for biomarker discovery[3]. About 95% of the
plasma proteome is accounted by only 10–12 highly abundant
proteins; the remaining 5% being in extremely low abundance.
However, it is this low abundance fraction of proteome that
contains tissue leakage proteins and proteins derived from
pathological sources containing information on the onset and
progression of a disease[1]. Hence, accurate profiling of changes in
protein expression patterns could give critical insights into the
development of a potential biomarker for clinical diagnostics. It is
a non-trivial task to identify and validate them due to the
abundance complexity as they get masked by large and abundant
proteins. A ‘‘divide and conquer’’ strategy works best in
exploration and cataloguing the plasma proteins[2,4,5]. By
depleting plasma of the high-abundance proteins, the sample
complexity is reduced[6] and makes the identification of low-
abundance proteins tenable[7–9]. Although there are various
methods used for depletion of one or more of the abundant
proteins in the plasma, immunoaffinity based method, which
allows simultaneous depletion of multiple high abundant proteins
is widely used[10,11].
Sample pre-fractionation using multi affinity removal system
(MARS) has been shown to improve detection of low abundance
proteins in plasma[12]. This technique employs a combination of
antibodies that can bind to the highly abundant proteins thereby
depleting their total concentration from plasma resulting in the
reduction of its dynamic range and enrichment of low abundance-
protein species. However, one of the potential drawbacks of
removal of abundant proteins (targeted proteins against which
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simultaneous removal of some less abundant proteins (non-
targeted proteins). Although there have been studies addressing
the questions of non-targeted removal of a few proteins and the
non-removal of some targeted ones, it is predominantly reported
that both these categories have negligible number of proteins[8,13]
and these effects are minimal. With the advent of high resolution
mass spectrometers it is now possible to identify proteins which
could not be identified earlier using instruments with lower
resolution and sensitivity. Thus, we tried to understand the extent
of removal of non-targeted proteins by MARS columns- Hu6,
Hu14 and Proteoprep 20 that targets the removal of 6, 14 and 20
abundant proteins respectively. Using an LTQ-Orbitrap instru-
ment, we intended to identify a high-confidence set of proteins
from the bound fraction and to ascertain if some of these proteins
are being specifically removed because of their interaction with
targeted proteins. The significance of such a study cannot be
overstated if we follow that most biomarkers are found in low
abundance in plasma. Since most high abundance proteins act as
carrier proteins and take away many other proteins with them
during MARS removal, there is a loss of proteins that may turn
out to be potential biomarkers.
Using multiple algorithms to identify high-confidence non-
targeted proteins and interaction analyses of high-abundance
proteins, we have identified 101 non-targeted proteins and shown
that non-targeted removal of proteins is not trivial as portrayed
earlier and attempted to observe sampling variations and MARS
column specific removal. We speculate that some proteins may be
specifically removed due to their interactions and propensity to
bind to high abundant proteins. To carry out an effective
biomarker discovery exercise, we believe that the MARS bound
fractions should not be ignored. Therefore, an integrative analysis
approach profiling the non-targeted proteins from the MARS
bound fraction along with the depleted one may prove better for
biomarker discovery pipelines.
Results
Plasma Depletion
Three human plasma samples were each depleted using three
different MARS cartridges (A6, A14 and S20). The depletion
efficiency of the three systems was above 90% for each of the
sample. A comparative efficiency of protein enrichment is shown
in Table 1. All the 9 eluted samples (3 samples with 3 cartridges)
were subjected to GeLC-MS as mentioned in the methods. Since
each lane of the gel was cut in 5 pieces, there were 45 fractions in
total from the 9 eluted samples. The total number of peptides
obtained from each fraction is shown in Table S1. However, since
all these peptides are not of high confidence, an integrated
bioinformatics workflow for high specificity peptide identification
from plasma was developed (Figure 1). In this workflow, separate
target-decoy searches were conducted in four different algorithms-
Sequest, X!Tandem, OMSSA and MassWiz. A stringent FDR of
,1% was applied. The objective of such an effort was to
characterize plasma proteins with high confidence, keeping false
positives to a bare minimum. Use of multiple algorithms increases
the statistical confidence[14] if the same peptide is picked up by
more than one search algorithm. The Venn diagrams in figure 2
illustrate the number of non-redundant peptides assigned by each
algorithm and a high mutual agreement is evident in most cases.
The total number of peptides (at,1%FDR) and selected high-
confidence peptides ($2 algorithms) are shown in figure S1. The
total number of peptides identified by at least one, two, three and
four algorithms is shown in Table S1. All peptides identified by a
single algorithm were discarded so as to keep a high confidence set
only. This prevents identification of an incorrect protein based on
a single peptide hit. As shown by Gupta et al., removing single
peptide hits leads to a substantial loss in true protein hits[15].
From this high-confidence set (identified by at least two
algorithms), the peptides were used for protein inference where
protein groups were formed as described in methods section. All
targeted proteins (those which are supposed to be removed by
MARS cartridge), keratins and immunoglobulins were removed
from the protein groups. The remaining protein groups were
reserved for analyses. From here on, we use the term ‘‘proteins’’
for ‘‘protein groups’’ that we have identified.
Analysis of bound fraction
The number of proteins identified from each fraction of the
depletion systems after excluding the target proteins of the
cartridge in consideration, are shown in Table 2. Redundancy
in the list of proteins was corrected manually. A total of 101
distinct plasma proteins were identified and their detailed
information is listed in Table S2. Proteins identified from three
plasma samples for a single cartridge were pooled and a non-
redundant list was made for the three depletion systems. The
number of proteins identified in different MARS is 45, 53 and 61
respectively for A6, A14 and S20 when the protein lists for all
samples were combined (Figure S2) indicating that the total
number of non-targeted proteins in the bound fraction increased
with increase in the numbers of proteins that are targeted for
removal. Further, 9, 18 and 21 proteins were found to be common
in at least two samples eluted from A6, A14 and S20 respectively
(Figure 3A) while 22, 17 and 10 proteins were eluted from at least
2 cartridges using a specific sample- S1, S2 and S3 respectively
(Figure 3B).
The identified proteins were sub-categorized as ‘‘common
proteins’’ and ‘‘unique proteins’’ based on the fact that if a protein
falls in any two cells of the 363 matrix in Table 2, it is considered
under ‘‘common proteins’’. The rest (found in a single sample and
a single MARS cartridge) were designated as ‘‘unique proteins’’.
The common proteins could be further classified as (A) Proteins
common between at least two different samples (Table S2A) and
(B) Proteins which are common in a particular sample but from
different cartridges (Table S2B) and (C) proteins that were unique
to a specific sample and cartridge (Table S2C). Thus, we identified
38 proteins that were eluted in at least 2 different samples (Group
A), 14 proteins that were eluted from any single sample but in
multiple cartridges (Group B) and 49 proteins that were unique to
a specific sample and cartridge (Group C). The matrix of identified
proteins with respect to the MARS column is depicted as a heat
map for direct visual comparison (Figure 4). The heat map
revealed that some proteins are constantly removed across
samples, cartridges or both. For instance Dermcidin, Apolipopro-
tein D, Apolipoprotein E, Elongation factor 1-alpha. These
proteins can be visualized in the upper part of the heat map. Of
the 101 proteins that we identified in this study, 53 proteins (28 in
group A, 9 in group B and 16 in group C) have been reported to
be present in the eluted fraction in earlier studies using various
depletion methods (Table S2). Thus, we are for the first time
reporting the presence of an additional 48 proteins in the MARS
bound fraction.
We also checked how many of the proteins that we found in the
eluted fraction are listed in the Plasma Proteome Database
(PPD)[16]. For this, the uniprot id and the corresponding Refseq/
Entrez ids of all 101 proteins were mined for the IPI accessions
and searched in Human Protein Reference Database (HPRD)[17]
and PPD. These periodically updated databases are a curated
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a reference for the proteomics community [17–21]. We found that
from our list of 101 proteins, 99 were present in HPRD and 95
were found in PPD depicting a high concordance with these
databases. The specificity of non-targeted protein removal can be
sample specific or MARS specific. Venn diagrams depicting the
proteins identified from different samples for a particular MARS
(Figure 3A) and different MARS for a particular sample (Figure 3B)
can reveal such effects. Figure 3A shows that A6 had 6, A14 had 8
and S20 had 5 proteins common to all samples. This suggests that
Figure 1. Overview of bioinformatics analysis workflow for mining the plasma peptides. Sequest, X!Tandem, OMSSA and MassWiz
algorithms were used to identify PSMs at ,1% FDR. All peptides identified by at least two algorithms were used for inferring the minimal protein list.
doi:10.1371/journal.pone.0024442.g001
Table 1. Separation efficiency of cartridges is shown for MARS A6, A14 and S20.
Depletion System
(supplier)
Average Plasma
Protein load(mg)
Average of Total protein
yield after depletion (mg)
Expected depletion
efficiency (%)
Observed depletion
efficiency (%)
A6 10 ml (720) 72.0 92–94 90
A14 10 ml (720) 61.2 94 91.5
S20 10 ml (720) 36.0 99 95
More than 90% efficiency was observed for all cartridges. All values given in the table are mean of three plasma samples.
doi:10.1371/journal.pone.0024442.t001
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figure 3B suggests 12, 5 and 3 proteins to be sample specific for
sample 1, sample 2 and sample 3 respectively since these were
found in all MARS for the particular sample used.
One of the major reasons for the removal of non-targeted
proteins might be their interaction with the targeted proteins.
Thus, to check the proteins that interact with the targeted proteins
we used Cytoscape which is a widely used network visualization
and interaction analysis tool. Cytoscape was used for creating
interaction networks for proteins that are targeted to be removed
by each of the MARS cartridges. The interaction networks are
shown in figure 5. These interacting partners were matched with
our protein list to check the overlap and evaluate the specificity of
the removal. 18, 20 and 24 non- targeted proteins were found to
interact with one or more of the targeted proteins in MARS A6,
A14 and S20 respectively. These proteins when combined make a
non-redundant list of 33 proteins indicating that of the 101
proteins that we identified 33 of them are known to interact with
the targeted abundant proteins.
Thus, our observations clearly indicate that non-targeted
proteins in the bound fraction are much higher in number. Some
of the proteins that we identified in the eluted fraction have earlier
been reported to be markers for certain disease states. For
instance- Retinol Binding Protein-4 has been reported to be a
biomarker for renal dysfunction and cardiovascular disease in type
2 diabetes [22]. Vitronectin concentrations have been reported to
predict the risk in patients undergoing coronary stenting[23].
S100A8 is identified as a biomarker of HPV-18 infected oral
squamous cell carcinomas by Lo et al.[24]. Serum paraoxonase
PON1 has been reported as a potential biomarker of organo-
phosphate toxicity[25]. Nicholas et al. have reported Apo A1 and
Lipocalin as biomarker for chronic obstructive pulmonary
disease[26].
Discussion
Plasma pre-fractionation has proved to be necessary since it
reduces the sample complexity and helps enrich low abundance
proteins by removing highly abundant proteins. However, it also
creates a problem due to concomitant removal of non-targeted
ones. Choosing a depletion system remains a trade-off between
Figure 2. Venn diagram of peptides identified by different algorithms across samples and cartridges. A large portion of peptides
cannot be picked by a single search algorithm and thus multiple algorithms can increase confidence as well as identify more peptides as shown.
doi:10.1371/journal.pone.0024442.g002
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reasons for the removal of the non-targeted proteins may be either
protein-protein or protein-antibody interactions. In this study,
protein-antibody interactions were not studied in detail since these
depletion systems have been proved to be sufficiently sensitive and
specific [8,13]. On the other hand interaction of targeted proteins
with other proteins seems to be the most plausible reason for the
removal of non-targeted proteins. For instance, albumin, a carrier
protein, is known to be bound with different small molecular
weight proteins [27,28]. This sort of binding could be specific or
non-specific. Gundry et.al.[28], have described the ‘albuminome’,
which consists of 35 proteins from plasma that are co-eluted with
albumin using anti HSA (human serum albumin) depletion system.
These were shown to be potential candidates for non-targeted
removal during albumin depletion. From our list of identified non-
targeted proteins we found 27 proteins matching with the list of
‘albuminome’. So, it is likely that the removal of these proteins is
due to the specific binding property of albumin with other
proteins.
Stempfer et al.[29] reported 24 proteins from the bound
fraction using MARS-6, of which 15 proteins matched with the
proteins identified in this study. A detailed assessment of IgY-12
depletion systems by Liu et al.[30], and also by Huang et al.[31]
pointed towards some non-targeted removal from depletion of
plasma or serum. From their studies, 24 and 5 proteins
respectively matched with our list. Similar efforts have been taken
by Zhou et al.[32] by depleting 6 most abundant proteins from
plasma. Gong et al.[33] have reported the removal of 129 non-
targeted proteins, the largest number while depleting six most
abundant proteins. However, in this the data analysis was carried
out using only Sequest and may have inadvertently over-
represented the number of proteins since single-peptide identifi-
cations from one algorithm are more prone to be false in
comparison to those from multiple algorithms. For instance, if we
had used a single algorithm (Sequest) to analyse our data we would
have identified 112 proteins from A6 bound fraction, whereas
using the stringent criteria of our study we identified 45 proteins
from the A6 bound fraction (data not shown). Further, in our
analysis we have removed all the immunoglobulin variants, keratin
family of proteins and variants of the respective targeted proteins.
In contrast to these studies, Bellei et al.[13] have shown MARS-
6 to be highly specific. Only 3 non-targeted proteins were
identified in the bound fraction using nano LC-CHIP-MS
Figure 3. (A) Comparison of proteins (IPI identifiers) from a specific cartridge. (B) Comparison of proteins (IPI identifiers) from a specific sample across
cartridges.
doi:10.1371/journal.pone.0024442.g003
Table 2. The numbers of unique non-targeted proteins
identified in the eluted fractions excluding variants of
immunoglobulin, targeted proteins and keratins from each
sample after depletion with the three cartridges are shown
here.
MARS
Sample A6 A14 S20
S1 24 36 33
S2 26 26 38
S3 10 18 16
doi:10.1371/journal.pone.0024442.t002
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protein removal remains a major issue in plasma proteomic
studies. But it is important that the identified proteins should be
unambiguous and highly-confident. Therefore stringency in
bioinformatics analysis for the identification of proteins in bound
fraction is the most important step. According to Tu et al.[8]; a
total of 23 proteins were found to be present in bound fractions of
MARS-7 and MARS-14, of which 9 proteins matched with our
data. A broad literature search points towards the fact that the
issue of non-targeted removal should be evaluated in detail.
Recently, Smith et al.[34] have analyzed the potential efficiency
of the three depletion systems that we have used. Interestingly, in
an attempt to identify the proteins from bound fraction using a
‘top-down’ approach they could not identify any non-targeted
proteins in the bound fraction. The stringent criterion for the
identification of proteins is important to understand non-targeted
removal of proteins during depletion of plasma. Mining the plasma
proteome has always been a major challenge. Interaction analysis
of different abundant proteins suggests that some specific removal
will always be there during depletion of different abundant
proteins from plasma. There are several targeted proteins which
may have a significant role in non-targeted removal. For eg,
Histidine rich glycoprotein and Antithrombin interact with
plasminogen, ATP Synthase subunit beta interacts with Plasmin-
ogen, Serum paraoxonase interacts with Apo-A1 etc. It is
important to know the proteins which could be removed
specifically.
While the evidence presented here is not enough to conclude
that these non-targeted proteins will not be found in the depleted
fraction of plasma but it will however definitely be an impediment
in proper quantitation of such proteins. The distribution of the
non-targeted proteins in the depleted and the bound fractions
might be dictated by the binding affinity of the non-targeted
proteins to the targeted proteins and the concentration of the non-
targeted protein in a particular plasma sample. Thus, if the
binding affinity of a particular non-targeted protein to the targeted
protein is low it is likely that a part of it will be eluted along with
the abundant targeted proteins while the rest will remain in the
depleted fraction. This understanding will ultimately help in
devising proper downstream analysis of depleted fraction from
plasma in discovery based clinical proteomic studies which now
rely heavily on the protein quantitation. However, it might be
prudent not to consider such proteins as biomarkers unless it has
been evaluated in large number of samples.
Conclusion
Analysis of plasma samples for the discovery of new disease
biomarkers holds great promise; but is fraught with challenges
[3,35,36]. The potential of affinity based pre-fractionation of
plasma can be maximized when the downstream workflow utilizes
both the fractions (flow-through and bound fraction) for analysis.
We have shown that the bound fractions contain important
plasma proteins which have been indicated to be relevant as
disease biomarkers. Contrary to general belief, our study reports
more proteins in non-targeted category. Using this approach for
simplifying the plasma proteome is more beneficial when both the
fractions are analyzed. The effect of MARS on enrichment of
sample is the next question to address and thus forms the
immediate focus of our next work. Further study on this aspect
would provide new insights after in-depth analysis of the depleted
fractions.
Materials and Methods
Sample Collection and Plasma Isolation
Blood samples were collected in EDTA vacutainer from three
healthy individuals. Ethics Committee f the Institute of Genomics
and Integrative Biology (Institutional human ethics committee,
IHEC) approved the collection of human blood samples. Written
consent from all the individuals were obtained on the day of
recruitment. The blood samples were stored upright at 4uC until
they were spun at 2500 rpm at 4uC for 15 minutes as mentioned in
Omenn et al [37]. The separated plasma was aliquoted and stored
at 280uC for further analysis.
Depletion of Plasma Samples
The depletion was performed according to the manufacturers’
protocol for all the three depletion cartridges. The list of targeted
proteins for each cartridge is given below. From here on, we use
Figure 4. Heat map depicting concordance of proteins within
and across cartridges.
doi:10.1371/journal.pone.0024442.g004
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cartridges.
A6:- Albumin, IgG, Antitrypsin, IgA, Transferrin, Heptoglobin.
A14:- Albumin, IgG, Antitrypsin, IgA, Transferrin, Haptoglo-
bin, Fibrinogen, Alpha 2-macroglobulin, Alpha 1-macroglobulin,
IgM, Apolipoprotein A1, Apolipoprotein A2, Complement C3,
Transthyretin.
S20:- Albumin, IgG, Transferrin, Fibrinogen, IgA, Alpha 2-
macroglobulin, IgMs, Alpha1- Antitrypsin, Complement C3,
Haptoglobin, ApoA1, ApoA2, Apo B, Alpha 1 Glycoprotein,
Ceruloplasmin, Complement C4, Complement A1q, IgD, Preal-
bumin, Plasminogen.
Sample Preparation and SDS-PAGE
The proteins in the bound fraction were concentrated from a
volume of 4 ml to about 300 ml using centrifugal concentrators
(Millipore 3kd). The samples were precipitated with 2D clean up
kit (Amersham) prior to SDS-PAGE. The protein pellets were
resuspended in 7 M urea, 2 M thiourea, 25 mM ammonium
bicarbonate buffer (pH 8.5). 30 mg of protein from each of the
three samples eluted using three cartridges was subjected to gel
electrophoresis on a 10% tricine gel and stained with phast gel
coomassie (Amersham).
In-Gel Digestion
Each lane of eluted fractions in the gel was excised and sliced
into 5 fractions. Each fraction was washed with LC-MS grade
water (Sigma) 2–3 times and destained at least twice with the
destaining solution [100%MeOH:50 mM Ammonium bicarbon-
ate (1:1)]. The gel pieces were then dehydrated in 100%
ACN:50 mM Ammonium bicarbonate (1:1) and reduced using
freshly prepared DTT (25 mM) for 20 minutes (55uC) and
alkylated using IAA (55 mM) for 30 minutes in dark at room
temperature. The samples were then dried using speed vac
(Eppendorf). Trypsin (promega V511A, 12.5 ng/ml) was added to
these samples and incubated for 30 minutes on ice until the gel
pieces swelled and then overlaid with 10 mM Ammonium
bicarbonate buffer. The tubes were left overnight at 37uC and
extraction of the tryptic peptides was carried out with 1% TFA in
30% ACN.
Nano-RP-LC MS/MS analysis
Lyophilized peptides were reconstituted with 2% ACN
supplemented with 0.1% formic acid. The peptides were subjected
to reverse phase chromatographic fractionation through split free
nano-LC system (EASY-nLC; Proxeon Biosystems now Thermo
Fisher Scientific) coupled to the LTQ Orbitrap mass spectrometer
(LTQ-Orbitrap XL, Thermo Fisher Scientific).
Chromatography was performed using two buffer systems, viz;
Buffer A- 2% ACN, 0.1% formic acid and Buffer B-98% ACN
and 0.1% formic acid. The pre-column (fused silica (f.s.) capillary
of 100 mm internal diameter, length 3 cm of Synergy reversed
phase C-18 beads) was equilibrated with 30 ml of buffer A at a flow
rate of 6 ml/min. The f.s. capillary of internal diameter 100 mm
and length 10 cm was pulled to make the nanospray tip/needle for
electrospray ionization. Synergy reversed phase C-18 beads were
then packed on to this nanospray needle and thus the analytical
column was ready, which was equilibrated with 10 ml of buffer A
at a flow rate of 0.8 ml/min. Samples were then loaded onto the
pre-column for desalting and then to the analytical column. The
peptides were separated using a 140 min stepwise gradient of 15%
Buffer B for 20 min, 45% for 110 min and 100% for 2–8 min at a
constant flow rate of 300 nl/min. The LTQ-Orbitrap XL mass
spectrometer was operated in data dependent MS/MS mode with
a MS survey scan (m/z 350 -2000) at resolution set to 60,000 in
FTMS mode followed by four data-dependent scans in ITMS
mode in which the four most intense ions were successively
subjected to CID (MS/MS). Dynamic mass exclusion was enabled
with a repeat count of once every 30 seconds for a list size of 500.
Database Searching and Statistical analysis
The RAW files obtained from 45 LC-MS/MS runs (5 gel
slices63 samples63 MARS) were converted to mascot generic
format (mgf) using msconvert.exe program from ProteoWi-
zard[38] version 1.6. These mgf files were then independently
searched with four different database search algorithms for
decreasing false positives in peptide identifications. The overview
of search and statistical analyses performed is summarized in
figure 1. We have used four algorithms namely- Sequest[39]
version 28.0.0.0, OMSSA[40] version 2.1.9, X!Tandem[41]
version Tornado and our in-house developed algorithm Mass-
Wiz[42] version 1.7.0.0 to search against Human IPI database[43]
(database v.3.74). Since the spectra acquisition was carried out in
an LTQ-Orbitrap XL instrument with LTQ for fragmentation,
the database searches were performed with 10 ppm precursor and
0.6 Da fragment ion tolerances. All cysteines were considered
modified with carbamidomethylation (+57.012) and a variable
modification of methionine oxidation (+15.9949) was also taken
into account. Tryptic digestion with a maximum of 2 missed
Figure 5. The interaction maps of (A) A6, (B) A14 and (C) S20 where the red squares denote targeted proteins; blue circles denote
all interaction partners while the non-targeted proteins are represented with green squares.
doi:10.1371/journal.pone.0024442.g005
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for keeping false positives to a minimum. A separate target-decoy
search strategy[44] was used for FDR estimation.
Sequest searches and FDR calculations were conducted using
Proteome Discoverer 1.1 and PSMs (Peptide Spectrum Matches)
from different runs were merged. OMSSA searches were queued
in a batch mode using a perl program and results were saved in
.csv format. The FDR was calculated on e-values using another
perl program. The results from different runs were merged
together. X!Tandem was also run through a Perl program in batch
mode. Another Perl program was used to parse XML results and
FDR was calculated based on e-values. The results from different
runs were then merged.
The in-house developed algorithm MassWiz was also used to
analyze the data. MassWiz was developed with a view to maximize the
use of information content from the MS/MS fragment spectra in a
high-throughput fashion. Target-Decoy strategy is inherently integrat-
ed into MassWiz search. All searches were conducted using the
aforementioned parameters. After database searches, the different runs
were merged as described earlier for other algorithms.
For all datasets, peptides identified by at least two algorithms
were selected for further analysis. This further increased
confidence and decreased false positives. By applying this stringent
criterion, the actual FDR is expected to be much lower than the
original FDR threshold of 1% applied earlier. Based on these
peptides, protein grouping was performed following the principles
of peptide parsimony as described by Nesvizhski and Aeber-
sold[45]. Briefly, the program groups the proteins where the
protein group representative must have either one unique peptide
or the group must have at least one unique peptide exclusively to
its members. For compiling a final list of proteins, only the selected
peptides ($2 algorithms) were mapped back to the proteins for
sequence coverage calculation. The peptides which had ambiguity
in group assignment (bridging multiple groups) were discarded. In
case of isoforms, if a particular isoform is identified by unique
peptide(s), it was designated as group representative. In cases
where all isoforms shared the peptide(s), the isoform with longest
protein length was designated as the group representative. The
proteins identified by a single peptide were manually validated as
per MIAPE guidelines[46]. The spectral images for validation
were generated using the pLabel tool in the pFind[47] suite. The
manual validation file is provided as Spreadsheet S1 and
annotated images are provided as Archive S1.
Protein Interaction Network Analysis
To create the interaction network of the targeted proteins, we
used Cytoscape[48] version 2.8. Uniprot identifiers of each target
protein were provided as input to the APID2NET[49] plugin to
build the network. Wherever there were multiple isoforms of the
target proteins, all were taken to build the interaction network.
The interaction networks were separately created for different
MARS.
Online data submission
The data associated with this manuscript may be downloaded
from ProteomeCommons.org Tranche using the following hash:
GHBbTxIbroyf1JPdTECnsFFChIcHNnIjLZzdWtKte8j892JB-
sRi3KF2/RdFvZmLspptDv4S/HJgyc+zC8hoDeoPP8J4AAAAA-
AAACow= =
The hash may be used to prove exactly what files were
published as part of this manuscript’s data set, and the hash may
also be used to check that the data has not changed since
publication.
Supporting Information
Figure S1 Total peptides pooled after 1%FDR from four
algorithms-Sequest, X!Tandem, OMSSA and MassWiz.
The peptides identified by at least 2 algorithms were selected for
further analysis.
(TIF)
Figure S2 Number of proteins identified in the bound
fraction from the three removal systems.
(TIF)
Table S1 Number of peptides identified by at least 1, 2,
3 and 4 algorithms. The four algorithms used were MassWiz,
SEQUEST, X!Tandem and OMSSA. The peptides identified by
$2 algorithms were selected for further analyses.
(DOC)
Table S2 List of all non-targeted proteins from the
bound fractions categorized as- (A) Proteins Common
between Samples, (B) Proteins Common in a particular
sample across different cartridge and (C) Proteins
Unique to a sample and cartridge.
(DOC)
Spreadsheet S1 List of manually validated peptides for
single peptide hit proteins, their raw spectral counts and
algorithms that identified the peptides.
(XLSX)
Archive S1 Annotated spectral images for the single
peptide hits.
(RAR)
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